Abstract
THE molecular mechanism responsible for the therapeutic activity of a drug is often suggested by the biochemical event which correlates best with clinical potency. Thus, if optical or geometrical isomers of a drug have markedly different clinical potencies, the most relevant biochemical effect should also exhibit isomeric specificity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Janssen, P. A., and Van Bever, W. F., in Current Developments in Psychopharmacology, 2 (edit. by Essman, W. E., and Valzelli, L.), 165–184 (Spectrum Publications, New York, 1975).
Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G. L., and Greengard, P., Proc. natn. Acad. Sci. U. S. A., 71, 1113–1117 (1974).
Miller, R. J., Horn, A. S., and Iversen, L. L., Molec. Pharmac., 10, 759–766 (1974).
Iversen, L. L., Rogawski, M. J., and Miller, R. J., Molec. Pharmac., 12, 217–224 (1976).
Seeman, P., and Lee, T., Science, 188, 1217–1219 (1975).
Anden, N.-E., Archs Pharmac., 283, 419–424 (1974).
Weismann, A., in The Phenothiazines and Structurally Related Drugs (edit. by Forrest, I. S., Carr, C. J., and Usdin, E.), 471–480 (Raven, New York, 1974).
Møller-Neilsen, I., Pedersen, V., Nymark, M., Franck, K. F., Boeck, V., Fjalland, B., and Christensen, A. V., Acta pharmac. tox., 33, 353–362 (1973).
Bruderlein, F. T., Humber, L. G., and Voith, K., J. med. Chem., 18, 185–188 (1975).
Lippman, W., Pugsby, T., and Marker, J., Life Sci., 16, 213–244 (1975).
Iversen, L. L., Science, 188, 1082–1089 (1975).
Enna, S. J., and Snyder, S. H., Brain Res., 100, 81–97 (1975).
Burt, D. R., Enna, S. J. Creese, I., and Snyder, S. H., Proc. natn. Acad. Sci U. S. A., 72, 4655–4659 (1975).
Creese, I., Burt, D. R., and Snyder, S. H., Life Sci., 17, 993–1002 (1975).
Pasternak, G. W., Snowman, A. M., and Snyder, S. H., Molec. Pharmac., 11, 735–744 (1975).
Bylund, D. B., and Snyder, S. H., Molec. Pharmac., 12, 568–580 (1976).
Bennett, J. P., Jr, and Snyder, S. H., Brain Res., 94, 523–544 (1975).
Bennett, J. P., Jr, and Snyder, S. H., Molec. Pharmac., 12, 373–389 (1976).
Yamamura, H. I., and Snyder, S. H., Proc. natn. Acad. Sci. U. S. A., 71, 1725–1729 (1974).
Young, A. B., and Snyder, S. H., Proc. natn. Acad. Sci. U. S. A., 70, 2832–2836 (1973).
Alexander, R. W., Davies, J. N., and Lefkowitz, R. J., Nature, 258, 437–440 (1975).
Bennett, J. P., Logan, W. J., and Snyder, S. H., Science, 178, 997–999 (1972).
Cheese, I., Burt, D. R., and Snyder, S. H., Science, 192, 481–483 (1976).
Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K., Proc. natn. Acad. Sci. U. S. A., 72, 4376–4380 (1975).
Snyder, S. H., and Bennett, J. P., Jr, A. Rev. Physiol., 38, 153–175 (1976).
Iversen, L. L., and Bloom, F. E., Brain Res., 41, 131–134 (1972).
Hokfelt, T., and Ljungdahl, A., Expl Brain Res., 14, 354–363 (1972).
Usdin, E., and Efron, D. H., Psychotropic Drugs and Related Compounds (US Department of Health Education and Welfare, Washington, DC, 1972).
Mielke, D. H., Gallant, D. M., Oelsner, T., Kessler, C. M., Tomlinson, W. K., and Cohen, G. H., Dis. Nerv. Syst., 36, 7–8 (1975).
Ayd, F. J., Int. Drug Therapy Newsletter, 6, 17–20 and 25–30 (1971); 7, 13–16 (1972); 10, 25–28 (1975).
Byck, R., in The Pharmacological Basis of Therapeutics (edit. by Goodman, L. S., and Gilman, A.), 152–200 (MacMillan, New York, 1975).
Creese, I., Feinberg, A., and Snyder, S. H., Eur. J. Pharmac., 36, 231–235 (1976).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
ENNA, S., BENNETT, J., BURT, D. et al. Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature 263, 338–341 (1976). https://doi.org/10.1038/263338a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/263338a0
This article is cited by
-
The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain
Molecular Psychiatry (2022)
-
The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation
Scientific Reports (2020)
-
The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Neuropsychopharmacology (2011)
-
Halopemide, a new psychotropic agent
Pharmaceutisch Weekblad Scientific Edition (1985)
-
2-[125Iodo]LSD, a new ligand for the characterisation and localisation of 5-HT2 receptors
Naunyn-Schmiedeberg's Archives of Pharmacology (1984)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.